VivoSeq
Metabolic & Endocrine

Diabetic Foot

151

Pipeline Programs↗

30

Active Trials↗

63

Companies Involved↗

Diabetic Foot is a highly competitive landscape with 151 programs across 63 companies. The most active players are Karyopharm Therapeutics Inc, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Jiangsu Topcel-KH Pharmaceutical Co., Ltd.. 32 therapies are approved with 30 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

77/100

Pipeline Velocity

32/100

Mech. Concentration

11/100

Completion Rate

76/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Karyopharm Therapeutics Inc

1 program

Phase 1Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

1 program

Phase 1J

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

1 program

Phase 1G

Guizhou Bailing Group Pharmaceutical Co Ltd

1 program

Phase 1LEO Pharma logo

LEO Pharma

1 program

Phase 1P

PluroGen Therapeutics, Inc

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical21

Bupivacaine

Innocoll

Insulin

Merck & Co.

Ciprofloxacin

Bayer

Sulfamethoxazole-Trimethoprim

National Institute of Allergy and Infectious Diseases (NIAID)

Antibiotic Duration

University Hospital, Geneva

Phase 124

Gentamicin

Schering-Plough

Doxycycline

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Collagenase Clostridium Histolyticum

Grupo Espanol de Tumores Neuroendocrinos

Epoetin Alfa

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Selinexor

Karyopharm Therapeutics Inc

Phase 244

Metformin Hydrochloride

Boehringer Ingelheim

Chlorhexidine

Dexcel Pharma Technologies Ltd.

Platelet Rich Plasma

Zagazig University

G-CSF

Arog Pharmaceuticals, Inc.

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 330

Ertapenem

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Tigecycline

Prism Pharmaceuticals

Daptomycin

Baxter Healthcare Corporation

Isosorbide Dinitrate

AstraZeneca

Linezolid

Pfizer

Approved32

Nitroglycerin

Viatris Specialty LLC

Tobramycin

Viatris Specialty LLC

Nitric Oxide

Mallinckrodt

Pirfenidone

Legacy Health System

Acetylcysteine

Arbor Pharmaceuticals, Inc.

Analysis

Modality Breakdown

95%

Small molecule

156 of 164 classified programs — the dominant modality here.

5%ALL OTHERSCell therapy53%Protein / enzyme21%Monoclonal antibody1<1%

Small molecule leads; the ring shows all 164 classified programs, each share of the total. Modality classified for 99% of 211 pipeline programs.

Analysis

Trial Status

197

clinical trials

Completed99 · 50%
Unknown status36 · 18%
Terminated27 · 14%
Recruiting13 · 7%
Not yet recruiting10 · 5%
Active, not recruiting6 · 3%
Other6 · 3%

Clinical Trials

Trial Activity

197 trials

Treating Diabetic Foot Ulcers, Comparing Two Topical Antimicrobial Agents, Dakin´s and Prontosan
Recruiting·—·N/A·NCT05132179·202 enrolled
A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers
Recruiting·ZZhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.·Phase 2·NCT06852976·60 enrolled
Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
Recruiting·MMicuRx·Phase 3·NCT05369052·865 enrolled
Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers
Recruiting·OOneness Biotech Co., Ltd.·Phase 2/3·NCT06531512·120 enrolled
Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers
Recruiting·UUniversity of the Punjab·Phase 1·NCT05610865·28 enrolled
Real-World Efficacy and Safety Analysis of Omadacycline for the Treatment of Diabetic Foot Infections and Acute Osteomyelitis
Recruiting·MMethodist Health System·N/A·NCT04714411·600 enrolled
NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers
Recruiting·NNOxy Health Products, LLC·Phase 1·NCT06402565·40 enrolled
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
Recruiting·EEnergenesis Biomedical Co., Ltd.·Phase 3·NCT05930210·230 enrolled
Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.
Recruiting·RRoyal Biologics·Phase 4·NCT07209475·248 enrolled
Clinical Observation and Mechanism Study of Yunnan Baiyao in Different Stages of Diabetic Foot
Recruiting·PPeking University Third Hospital·Phase 4·NCT06062576·100 enrolled
Multi-center Clinical Observation and Mechanism Study of Yunnan Baiyao in Different Stages of Diabetic Foot Ulcer
Recruiting·PPeking University Third Hospital·Phase 4·NCT06197412·100 enrolled
Efficacy of Placental Membrane Dressings in Accelerating Diabetic Foot Healing
Recruiting·BBioXTek·Phase 4·NCT07326553·30 enrolled
Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers
Recruiting·EEluciderm Inc·Phase 1/2·NCT07396376·15 enrolled
A Feasibility Trial to Investigate the Safety and Between-group Effect Size of STIMULAN VG and Standard of Care (SoC) in Participants With Diabetic Foot Osteomyelitis
Active, not recruiting·BBiocomposites Ltd·Phase 2·NCT05539963·61 enrolled
Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers
Active, not recruiting·JJiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.·Phase 2·NCT06189638·90 enrolled
Page 1 of 14

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)